Evommune (EVMN) Payables (2024 - 2026)

Evommune (EVMN) has 3 years of Payables data on file, last reported at $4.0 million in Q1 2026.

• Quarterly Payables changed N/A year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (changed N/A YoY) and the FY2025 annual result came in at $7.8 million, down 6.15% from the prior year.
• Payables eased to $4.0 million in Q1 2026 per EVMN's latest filing, from $7.8 million in the prior quarter.
• Across five years, Payables topped out at $8.3 million in Q4 2024 and bottomed at $3.6 million in Q3 2025.
• The 3-year median for Payables is $5.9 million (2025), against an average of $5.9 million.
• Peak annual rise in Payables reached 6.15% in 2025, while the deepest fall reached 6.15% in 2025.
• Tracing EVMN's Payables over 3 years: stood at $8.3 million in 2024, then declined by 6.15% to $7.8 million in 2025, then plunged by 47.85% to $4.0 million in 2026.
• Per Business Quant, the three latest EVMN Payables figures stand at $4.0 million (Q1 2026), $7.8 million (Q4 2025), and $3.6 million (Q3 2025).

Peer Comparison